Introduction: Currently, there is no approved therapeutic entity for coronavirus disease 2019
(COVID-19) and clinicians are primarily relying on drug repurposing. However, findings …

Cytokine release syndrome in COVID-19 is characterized by hyperinflammation which
manifests as ARDS, multi-organ failure, and high inflammatory parameters. Tocilizumab, an …

At present, there are no proven agents for treatment of coronavirus disease (COVID-19). The
available evidence has not allowed guidelines to clearly recommend any drugs outside the …

Objective To study the treatment outcomes with tocilizumab in patients with COVID-19 ARDS
and hyperinflammation using the World Health Organization (WHO) COVID-19 ordinal scale …

Hyperinflammation is associated with increased mortality in coronavirus disease 2019
(COVID-19). In this retrospective, uncontrolled patient cohort with moderate-severe COVID …

Background Global randomised controlled trials of the anti-IL-6 receptor antibody
tocilizumab in patients admitted to hospital with COVID-19 have shown conflicting results but …

BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic …

Background: Immunomodulatory drugs have been used in patients with severe COVID-19.
The objective of this study was to evaluate the effects of two different strategies, based either …

Objectives Severe COVID-19 is associated with immune dysregulation and
hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; …

Abstract Objectives Interleukin (IL)-6 inhibitors are administered to treat patients hospitalized
with COVID-19. In 2021, due to shortages, different dosing regimens of tocilizumab, and a …